- Pre-clinical data for Celltrion’s monoclonal antibody treatment regdanvimab (CT-P59) shows significant reduction in viral load of SARS-CoV-2, with no significant difference observed in the neutralisation titres against wild type SARS-CoV-2
- Celltrion has completed patient enrolment of 1,300 people in a global Phase III clinical trial to evaluate the efficacy and safety of CT-P59
- Celltrion to commence further investigation into neutralisation activity of CT-P59 against other emerging COVID-19 variants
INCHEON, South Korea–(BUSINESS WIRE)–Celltrion Group today announced preliminary pre-clinical results for regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment, with data demonstrating that CT-P59 has a neutralising effect against the South African variant in an in vivo model. The study demonstrated that CT-P59 treatment, at a clinically relevant dose, results in a significant reduction in viral load of SARS-CoV-2. The manuscript describing this pre-clinical data is available on the pre-print server bioRxiv and is concurrently undergoing scientific peer-review for potential publication.
This pre-clinical study assessed the neutralisation effect of CT-P59 against the South African variant, using a clinically relevant dose. CT-P59 demonstrated reduction in the binding affinity against the receptor binding domain (RBD) in the three mutations (K417N, E484K and N501Y substitutions) of the South African variant. In addition, CT-P59 showed a reduced susceptibility against the South African variant in a live virus and pseudo-virus assay in vitro study. However, there was no significant difference observed in the respiratory viral infection in the upper and lower respiratory tracts when exposed with SARS-CoV-2 wild type and the South African variants in the study. Taken together, the reduced effect in in vitro neutralisation of CT-P59 is unlikely to compromise the in vivo therapeutic potency against the variant in the respiratory tract, especially at a clinical dose.
“We are encouraged by the new data, which reinforces that Celltrion’s CT-P59 treatment could be effective against the South African variant and variant mutations,” said Dr. HoUng Kim, Ph.D., Head of Medical and Marketing Division at Celltrion Healthcare. “Faced with the rapid spread of COVID-19 variants, global access to effective antibody treatment is fundamentally important to reduce the disease progression rate to severe COVID-19 and help outpatients avoid hospitalisation and alleviate the burden on the health care system. We have commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging strains in the UK and South Africa and we will continue to further investigate the neutralising antibodies and other responses to protect against current SARS-CoV-2 strains and emerging variants .”
Celltrion’s global Phase III clinical trial to further evaluate the efficacy and safety of CT-P59 is ongoing in 13 countries including the U.S., Spain and Romania, having recently completed patient enrolment of 1,300 people.
– ENDS –
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us.
About regdanvimab (CT-P59)
CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus. In vitro and in vivo pre-clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD and significantly neutralise the wild type and mutant variants of concern including the UK variant (B.1.17). In in vivo models, CT-P59 effectively reduced the viral load of SARS-CoV-2 and inflammation in lung. Results from the global Phase I clinical trial of CT-P59 demonstrated a promising safety, tolerability, antiviral effect and efficacy profile in patients with mild symptoms of COVID-19.1 Celltrion also has recently commenced the development of a neutralising antibody cocktail with CT-P59 against new emerging variants of SARS-CoV-2.
References
1 Celltrion Data on file
Contacts
For further information please contact:
Holly Barber
hbarber@hanovercomms.com
+44 (0) 07759 301620
Donna Curran
dcurran@hanovercomms.com
+44 (0) 7984 550312